Want to see CRL full AI Analyst Report?
CRL Stock Chart & Stats
$183.88
-$0.50(-0.26%)
At close: 4:00 PM EST
$183.88
-$0.50(-0.26%)
Day’s Range― - ―
52-Week Range$144.26 - $228.88
Previous CloseN/A
Volume179.29K
Average Volume (3M)896.94K
Market Cap
$11.11B
Enterprise Value$11.65B
Total Cash (Recent Filing)$191.83M
Total Debt (Recent Filing)$3.06B
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Aug 12, 2026EPS Estimate
2.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.75
Shares Outstanding48,167,730
10 Day Avg. Volume742,887
30 Day Avg. Volume896,939
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.19
Price to Sales (P/S)2.51
P/FCF Ratio19.47
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue2.89
Enterprise Value/Gross Profit9.08
Enterprise Value/Ebitda40.09
Forecast
1Y Price Target
$208.40Price Target Upside13.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)11.1
Revenue Forecast (FY)$3.85B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained positive operating cash flow and material free cash flow provide a durable liquidity buffer to fund operations, targeted M&A, share repurchases and debt service while earnings recover. Absolute cash generation reduces refinancing and short-term liquidity risk.
Diversified, Repeatable Fee-for-service ModelA broad suite of outsourced R&D, preclinical safety and manufacturing support creates recurring, project-based revenue and customer stickiness. Specialized regulated infrastructure and long R&D pipelines underpin midterm demand resilience and predictable backlog conversion.
Strategic Portfolio And Supply ActionsTargeted M&A and divestitures are reshaping the portfolio toward higher‑value capabilities (NAMs, in‑vitro NGS) and securing NHP supply. These structural moves reduce operational bottlenecks and should sustainably improve margin profile and service reliability over time.
Bears Say
Profitability Erosion And Margin CompressionMaterial margin deterioration and a shift to TTM net losses weaken earnings quality and return generation. Restoring historical gross and net margins requires sustained revenue mix improvement, cost realization and execution of savings; until then profitability is structurally impaired.
Moderate-to-elevated LeverageDebt roughly in line with equity and reported net leverage pressures constrain financial flexibility. Elevated leverage raises interest and refinancing sensitivity, limits capacity for opportunistic investment, and increases downside risk if margins or cash flow fail to normalize.
Segment-level Demand And Cost Pressure (RMS & DSA)Core segments face durable headwinds: RMS shipment timing and higher NHP costs, plus DSA study-related cost increases, reduce organic growth and compress segment margins. Persistent sub‑segment softness delays consolidated recovery and makes overall margin improvement harder to achieve.
CRL FAQ
What was Charles River Laboratories Intl’s price range in the past 12 months?
Charles River Laboratories Intl lowest stock price was $144.26 and its highest was $228.88 in the past 12 months.
What is Charles River Laboratories Intl’s market cap?
Charles River Laboratories Intl’s market cap is $11.11B.
When is Charles River Laboratories Intl’s upcoming earnings report date?
Charles River Laboratories Intl’s upcoming earnings report date is Aug 12, 2026 which is in 40 days.
How were Charles River Laboratories Intl’s earnings last quarter?
Charles River Laboratories Intl released its earnings results on May 07, 2026. The company reported $2.06 earnings per share for the quarter, beating the consensus estimate of $1.944 by $0.116.
Is Charles River Laboratories Intl overvalued?
According to Wall Street analysts Charles River Laboratories Intl’s price is currently Undervalued.
Does Charles River Laboratories Intl pay dividends?
Charles River Laboratories Intl does not currently pay dividends.
What is Charles River Laboratories Intl’s EPS estimate?
Charles River Laboratories Intl’s EPS estimate is 2.73.
How many shares outstanding does Charles River Laboratories Intl have?
Charles River Laboratories Intl has 48,167,730 shares outstanding.
What happened to Charles River Laboratories Intl’s price movement after its last earnings report?
Charles River Laboratories Intl reported an EPS of $2.06 in its last earnings report, beating expectations of $1.944. Following the earnings report the stock price went down -0.028%.
Which hedge fund is a major shareholder of Charles River Laboratories Intl?
Currently, no hedge funds are holding shares in CRL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Charles River Labs Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$208.40 (13.33% Upside)
$208.40 (13.33% Upside)
Blogger Sentiment
Neutral
CRL Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 429.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 16.6%
Last 30 Days ▲ 31.6%
Last 30 Days ▲ 31.6%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.47%
12-Months-Change
Fundamentals
Return on Equity
-5.74%
Trailing 12-Months
Asset Growth
1.95%
Trailing 12-Months
Company Description
Charles River Laboratories Intl
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
CRL Company Deck
CRL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: near-term operational and margin headwinds (Q1 organic revenue decline, margin compression, negative free cash flow in the quarter and segment-specific pressures in RMS and DSA) were weighed against clear strategic actions and forward-looking levers (acquisitions to secure NHP supply and expand NAMs, completed divestitures, $100M incremental cost savings in 2026, $300M+ cumulative savings, strong bookings/net book-to-bill and a $200M share repurchase). Management reaffirmed FY guidance for organic revenue and EPS, expects meaningful margin expansion in the second half, and signaled improving demand/proposal trends—resulting in a mix of near-term softness but constructive medium-term outlook.View all CRL earnings summariesCRL Revenue Breakdown
21.07% RMS
59.84% DSA
19.09% Manufacturing

CRL Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$208.40
▲(13.33% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
1.10% Insiders
44.43% Mutual Funds
0.20% Other Institutional Investors
24.73% Public Companies and
Individual Investors








